Confronto
Afamelanotide vs. Gonadorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
75921-69-6
33515-09-2
Peso molecolare
1646.87 g/mol
1182.29 g/mol
Emivita
12 h
0.1 h
Sequenza
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Meccanismo d'azione
Afamelanotide
Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone. It differs from native α-MSH by two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — which make it metabolically more stable and more potent. As an agonist at the melanocortin-1 receptor (MC1R) on melanocytes, it activates adenylate cyclase, raises cAMP and increases tyrosinase activity via the transcription factor MITF. This shifts pigment synthesis toward eumelanin, which absorbs UV and visible light and has antioxidant properties — the presumed mechanism of photoprotection in EPP.
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
4
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
4
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Afamelanotide and Gonadorelin?
- Afamelanotide is classified as "Ricerca (altro)", while Gonadorelin is classified as "Ricerca (altro)". Afamelanotide: Afamelanotide (brand name Scenesse) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin-1 receptor agonist. Unlike most peptides covered here, it is a regularly approved medicine: EMA approval in 2014/2015, FDA approval in 2019, in each case as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It promotes eumelanin formation in the skin. Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Afamelanotide or Gonadorelin?
- The highest available evidence level is "RCT sull'uomo" for Afamelanotide and "Studio sull'uomo" for Gonadorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Afamelanotide and Gonadorelin in Germany and the United States?
- Germania: Afamelanotide — Su prescrizione, Gonadorelin — Su prescrizione. Stati Uniti: Afamelanotide — Su prescrizione, Gonadorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.